ImmuneBridge Inc.

SAN FRANCISCO, CA · Founded 2022 · CIK 0001960306 · Biotech · Private

Umbilical cord blood stem cell therapeutics derived from publicly banked samples

immunebridge.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$16M
2 Form D · Apr 2025
18 months since last filing
Contracts
—
No federal contracts on record
Patents
4
1 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$10,150,000
Private capital raisedForm D · SEC$5,632,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2526GENTEL BIOSCIENCES INC—$2.7M
2527Insilico Medicine, Inc.—$20M
2528Nuvectis Pharma, Inc.—$16M
2529ImmuneBridge Inc.—$16M
2530IpiNovyx Bio, Inc.—$7.0M
2531Lang Artificial Intelligence, Inc.—$11M
2532STEMLINE THERAPEUTICS INC—$2.6M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • Omri Amirav-DroryDirector
  • Gregory BonfiglioDirector
  • Thomas FarrellDirector
  • Nadiya IshnazarovaDirector
  • Alicia JacksonDirector
  • Stuart JacobsonDirector · Executive Officer
  • Dylan MorrisDirector
  • Peretz PartenskyDirector · Executive Officer
  • Mary WarrenDirector
  • Cheryl ZimberlinDirector

Patents

USPTO · 1 granted of 4

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.